WHO se­cures three li­cens­ing deals to boost Covid vac­cine and as­say prod­uct op­tions

The World Health Or­ga­ni­za­tion has se­cured li­cens­ing agree­ments with Medi­gen Vac­cine Bi­o­log­ics, the Uni­ver­si­ty of Chile and the Span­ish Na­tion­al Re­search Coun­cil (CSIC) to in­crease the num­ber of Covid-19 vac­cine and as­say prod­uct op­tions for world­wide use. The li­cens­ing agree­ments fall un­der WHO’s Covid-19 Tech­nol­o­gy Ac­cess Pool (C-TAP).

Medi­gen is the first pri­vate man­u­fac­tur­er, as well as the first vac­cine mak­er, to en­ter an agree­ment with C-TAP. The Tai­wan-based biotech is li­cens­ing its Covid-19 vac­cine, MVC COVID-19, and pro­vid­ing staff train­ing to man­u­fac­tur­ers. The pro­tein sub­unit vac­cine, which has emer­gency use au­tho­riza­tion in Tai­wan, has had three mil­lion dos­es ad­min­is­tered in sev­en coun­tries, ac­cord­ing to a WHO press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER